Jill A Livengood

US Patent:

20100144015, Jun 10, 2010

Filed:

Dec 4, 2009

Appl. No.:

12/631629

Inventors:

Dan T. Stinchcomb - Fort Collins CO, US
Jill A. Livengood - Fort Collins CO, US
O'Neil Wiggan - Fort Collins CO, US
Richard Kinney - Fort Collins CO, US
Jorge Osorio - Mount Horeb WS, US

International Classification:

C12N 7/00
C12N 7/01

US Classification:

4352351

Abstract:

Embodiments herein report methods, compositions and uses for inducing and/or accelerating viral growth. In certain embodiments, methods, compositions and uses generally related to copolymer compositions for inducing viral growth, reducing lag time and/or increasing viral plaque size. In other embodiments, methods, compositions and uses of copolymer compositions can be for inducing flaviviral growth, reducing lag in growth and/or increasing plaque size.

US Patent:

20220332800, Oct 20, 2022

Filed:

Sep 20, 2019

Appl. No.:

17/295770

Inventors:

- Cambridge MA, US
Isamu TSUJI - Cambridge MA, US
Jill A. LIVENGOOD - Fort Collins CO, US
Hansi DEAN - Weston MA, US

Assignee:

Takeda Vaccines, Inc. - Cambridge MA

International Classification:

C07K 16/10
A61K 39/42
A61K 45/06
G01N 33/569

Abstract:

The present invention provides isolated monoclonal antibodies, or antigen-binding portions thereof, that bind to ZIKV glycoproteins, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies, or antigen-binding portions thereof, according to the present invention are useful for inhibiting or neutralizing ZIKV activity, thus providing a means of treating or preventing ZIKV infection in humans. The antibodies, or antigen-binding portions thereof, according to the present invention may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.

US Patent:

20200061151, Feb 27, 2020

Filed:

Sep 5, 2019

Appl. No.:

16/561755

Inventors:

- Cambridge MA, US
- Atlanta GA, US
Richard M. KINNEY - Fort Collins CO, US
Jill A. LIVENGOOD - Fort Collins CO, US

International Classification:

A61K 38/16
A61K 31/7048
A61K 39/12
A61K 31/713
C07K 14/005
C07K 14/18
C07K 19/00
C12N 15/09
C12N 15/861

Abstract:

Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.

US Patent:

20180251737, Sep 6, 2018

Filed:

Dec 28, 2017

Appl. No.:

15/856770

Inventors:

- Cambridge MA, US
Jill A. Livengood - Fort Collins CO, US
O'Neil Wiggan - Fort Collins CO, US
Richard Kinney - Fort Collins CO, US
Jorge Osorio - Mount Horeb WI, US

International Classification:

C12N 7/00

Abstract:

Embodiments herein report methods, compositions and uses for inducing and/or accelerating viral growth. In certain embodiments, methods, compositions and uses generally related to copolymer compositions for inducing viral growth, reducing lag time and/or increasing viral plaque size. In other embodiments, methods, compositions and uses of copolymer compositions can be for inducing flaviviral growth, reducing lag in growth and/or increasing plaque size.

US Patent:

20170290884, Oct 12, 2017

Filed:

Apr 20, 2017

Appl. No.:

15/492981

Inventors:

- Atlanta GA, US
Claire Kinney - Fort Collins CO, US
Richard M. Kinney - Fort Collins CO, US
Jill A. Livengood - Fort Collins CO, US

International Classification:

A61K 38/16
A61K 39/12
C12N 15/09
C12N 15/861
C07K 19/00
C07K 14/18

Abstract:

Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.

US Patent:

20150010983, Jan 8, 2015

Filed:

Sep 19, 2014

Appl. No.:

14/491805

Inventors:

- Deerfield IL, US
Jill A. Livengood - Fort Collins CO, US
O'Neil Wiggan - Fort Collins CO, US
Richard Kinney - Fort Collins CO, US
Jorge Osorio - Mount Horeb WS, US

International Classification:

C12N 7/00

US Classification:

435239

Abstract:

Embodiments herein report methods, compositions and uses for inducing and/or accelerating viral growth. In certain embodiments, methods, compositions and uses generally related to copolymer compositions for inducing viral growth, reducing lag time and/or increasing viral plaque size. In other embodiments, methods, compositions and uses of copolymer compositions can be for inducing flaviviral growth, reducing lag in growth and/or increasing plaque size.

US Patent:

20140271715, Sep 18, 2014

Filed:

Mar 13, 2014

Appl. No.:

14/209921

Inventors:

Daniel T. Stinchcomb - Fort Collins CO, US
Jill A. Livengood - Fort Collins CO, US
Lazlo Varga - Fort Collins CO, US

Assignee:

INVIRAGEN, INC. - Fort Collins CO

International Classification:

A61K 39/12
A61K 47/26
A61K 47/22
A61K 47/42

US Classification:

4242181

Abstract:

Embodiments herein relate to compositions of and methods for live attenuated alphaviruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated alphaviruses and compositions to reduce inactivation and/or degradation of the live, attenuated alphavirus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated alphavirus composition may include HEPES buffer. In other embodiments, the HEPES buffer may further include a carbohydrate and gelatin and/or a salt.